AZNAstraZenecaRunning, no new patients
A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 454 (final count)
- Started
- Oct 28, 2021
- Main results expected
- Jun 9, 2026
- Fully finished
- Jul 30, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression Free Survival (PFS) by Blinded Independent Central Review (BICR)
Measured over: Until progression or death, assessed up to approximately 12 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05048797 · record last updated 2026-10-21 · checked 2026-11-09 15:47 UTC